ProCE Banner Activity

PD-L1 Testing in the Setting of Progressive NSCLC After Chemotherapy

Multimedia
Leora Horn, MD, MSc, FRCPC, provides insight on the optimal management of patients with progressive advanced squamous NSCLC with unknown PD-L1 expression.

Released: June 04, 2018

Share

Faculty

Leora Horn

Leora Horn, MD, MSc

Assistant Professor, Hematology Oncology/Medicine
Vanderbilt Ingram Cancer Center
Vanderbilt University
Nashville, Tennessee

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

AstraZeneca

Bristol Myers Squibb

Celgene TEXT Only

Genentech TEXT Only

Lilly

Merck Oncology

Novartis Pharmaceuticals Corporation

Takeda Oncology

Learning Objectives

  • Plan treatment strategies for patients with NSCLC and disease progression on or after platinum-containing chemotherapy based on available data, treatment guidelines, and expert recommendations

Faculty Disclosure

Primary Author

Leora Horn, MD, MSc

Assistant Professor, Hematology Oncology/Medicine
Vanderbilt Ingram Cancer Center
Vanderbilt University
Nashville, Tennessee

Leora Horn, MD, MSc, FRCPC, has disclosed that she has received consulting fees from AbbVie, AstraZeneca, Bristol-Myers Squibb, Genentech, Lilly, Merck, and Xcovery and funds for research support from Boehringer Ingelheim and Xcovery.

Staff Disclosure

Staff

Rachael M. Andrie, PhD

Clinical Editor

Rachael M. Andrie, PhD, has no real or apparent conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no real or apparent conflicts of interest to report.